Cerner cardiovascular solutions enable cardiologists to automate functions across the continuum of care. Built upon the Cerner Millennium architecture, Cerner’s PowerChart Cardiovascular solution unifies cardiovascular diagnostic activities, therapeutic interventions and follow-up regimens into a single workflow, integrated with the electronic health record (EHR).  PowerChart Cardiovascular gives the cardiologist the ability to view images in context with Cerner’s cardiovascular workflow manager utilizing the integration with the Merge viewer.

 

November 3, 2011 – Medtronic announced the first implant in a clinical trial in Japan that will evaluate the safety and effectiveness of the Medtronic CoreValve System.

November 3, 2011 – Lantheus Medical Imaging announced important changes to the U.S. product label for Definity Vial for (perflutren lipid microsphere) Injectable Suspension. The contrast agent is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

November 3, 2011 – New study indicates strong diagnostic ability of treadmill exercise stress testing to uncover Long QT syndrome (LQTS) in patients.  Here, investigators from the Mayo Clinic show how the recovery phase displays significant and maladaptive changes in the QTc unveiling the most common LQTS type, LQT1. The study, published in the November edition of HeartRhythm, the official journal of the Heart Rhythm Society, is the largest, single-center study of treadmill exercise stress testing in patients with genetically proven LQTS as well as those who were dismissed as normal.

The U.S. Food and Drug Administration (FDA) today approved the first transcatheter aortic heart valve in the United States - the Sapien THV. Experts say the approval will open a new chapter in how patients with severe aortic valve stenosis will be treated, without surgery.

The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The stent uses the same drug and biocompatible polymer as the Xience V everolimus-eluting coronary stent system, but features an enhanced stent design and a delivery system designed for greater flexibility, better radial strength, longitudinal strength and more accurate stent placement.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now